{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T19:30:02Z","timestamp":1793734202036,"version":"4.6.1"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:p>Intravitreal anti-vascular endothelial growth factor (VEGF) therapy has fundamentally transformed the management of retinal and choroidal neovascular diseases. Despite its proven efficacy, long-term reliance on repeated intravitreal injections imposes a substantial burden on patients and healthcare systems. Real-world studies consistently demonstrate reduced adherence and inferior visual outcomes compared with randomized clinical trials. These limitations have driven interest in alternative, non-intravitreal routes of anti-VEGF delivery aimed at reducing treatment burden while maintaining therapeutic efficacy. This narrative review provides a comprehensive evaluation of suprachoroidal, systemic, transscleral, episcleral, subretinal, and topical non-intravitreal delivery strategies. Emphasis is placed on ocular pharmacokinetic barriers, pharmacodynamic requirements for sustained VEGF suppression, reasons for historical failures, and the translational maturity of emerging experimental platforms. While selected approaches, particularly suprachoroidal and gene-based strategies, show encouraging early results, intravitreal anti-VEGF therapy continues to represent the standard of care for ocular neovascular diseases.<\/jats:p>","DOI":"10.4103\/ijo.ijo_3226_25","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T16:01:02Z","timestamp":1777478462000},"page":"707-714","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Non-intravitreal anti-vascular endothelial growth factor delivery for ocular neovascular diseases: Current status and future directions"],"prefix":"10.4103","volume":"74","author":[{"given":"Shrinivas M","family":"Joshi","sequence":"first","affiliation":[{"name":"Department of Vitreoretina, M M Joshi Eye Institute, Hubli, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giriraj","family":"Vibhute","sequence":"additional","affiliation":[{"name":"Department of Vitreoretina, M M Joshi Eye Institute, Hubli, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shailesh M","family":"Rao","sequence":"additional","affiliation":[{"name":"Department of Vitreoretina, M M Joshi Eye Institute, Hubli, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apoorva","family":"Ayachit","sequence":"additional","affiliation":[{"name":"Department of Vitreoretina, M M Joshi Eye Institute, Hubli, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guruprasad","family":"Ayachit","sequence":"additional","affiliation":[{"name":"Department of Vitreoretina, M M Joshi Eye Institute, Hubli, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"key":"R1-20261103","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/nrd.2015.17","article-title":"Ten years of anti-vascular endothelial growth factor therapy","volume":"15","author":"Ferrara","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"R2-20261103","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N Engl J Med"},{"key":"R3-20261103","first-page":"1025","article-title":"Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration (ANCHOR study)","volume":"113","author":"Brown","year":"2006","journal-title":"Ophthalmology"},{"key":"R4-20261103","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal aflibercept for neovascular age-related macular degeneration (VIEW 1 and VIEW 2)","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"key":"R5-20261103","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","article-title":"Ranibizumab and bevacizumab for neovascular age-related macular degeneration (CATT)","volume":"364","author":"Martin","year":"2011","journal-title":"N Engl J Med"},{"key":"R6-20261103","first-page":"1","article-title":"Ranibizumab according to need: A treatment paradigm","volume":"27","author":"Spaide","year":"2007","journal-title":"Retina"},{"key":"R7-20261103","first-page":"2044","article-title":"Real-world visual outcomes of anti-VEGF therapy for neovascular age-related macular degeneration","volume":"122","author":"Holz","year":"2015","journal-title":"Ophthalmology"},{"key":"R8-20261103","first-page":"135","article-title":"Real-world outcomes of anti-VEGF therapy in neovascular age-related macular degeneration","volume":"40","author":"Gillies","year":"2020","journal-title":"Retina"},{"key":"R9-20261103","first-page":"e1","article-title":"Non-adherence to intravitreal anti VEGF therapy and its impact on visual outcomes","volume":"98","author":"Schuster","year":"2020","journal-title":"Acta Ophthalmol"},{"key":"R10-20261103","first-page":"2231","article-title":"Intraocular pressure changes following intravitreal injection of anti VEGF agents","volume":"34","author":"Storey","year":"2014","journal-title":"Retina"},{"key":"R11-20261103","first-page":"1636","article-title":"Aflibercept related sterile intraocular inflammation","volume":"122","author":"Hahn","year":"2015","journal-title":"Ophthalmology"},{"key":"R12-20261103","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/IAE.0000000000000399","article-title":"Systemic safety and adverse events after intravitreal anti VEGF therapy","volume":"34","author":"Avery","year":"2014","journal-title":"Retina"},{"key":"R13-20261103","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S0014-4835(03)00213-6","article-title":"The blood\u2013retinal barriers system","volume":"78","author":"Cunha-Vaz","year":"2004","journal-title":"Exp Eye Res"},{"key":"R14-20261103","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0039-6257(02)00326-0","article-title":"Drug transport to the posterior segment of the eye","volume":"47","author":"Maurice","year":"2002","journal-title":"Surv Ophthalmol"},{"key":"R15-20261103","first-page":"355","article-title":"Permeability of ocular tissues","volume":"1","author":"Raghava","year":"2004","journal-title":"Mol Pharm"},{"key":"R16-20261103","first-page":"107","article-title":"Current and future ophthalmic drug delivery systems","volume":"57","author":"Del Amo","year":"2017","journal-title":"Prog Retin Eye Res"},{"key":"R17-20261103","first-page":"3653","article-title":"Human scleral permeability: Effects of age, race, and diabetes","volume":"47","author":"Olsen","year":"2006","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R18-20261103","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jconrel.2005.09.049","article-title":"Iontophoresis: A non-invasive ocular drug delivery platform","volume":"110","author":"Eljarrat-Binstock","year":"2006","journal-title":"J Control Release"},{"key":"R19-20261103","first-page":"160","article-title":"Transscleral drug delivery: A review","volume":"118","author":"Gratieri","year":"2017","journal-title":"Eur J Pharm Biopharm"},{"key":"R20-20261103","first-page":"2439","article-title":"Ocular distribution of periocularly applied drugs: Experimental models","volume":"41","author":"Einmahl","year":"2000","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R21-20261103","first-page":"1035","article-title":"Suprachoroidal axitinib for neovascular retinal disease: Early clinical results","volume":"7","author":"Dugel","year":"2023","journal-title":"Ophthalmol Retina"},{"key":"R22-20261103","first-page":"368ra174","article-title":"AXT107, a collagen derived peptide, inhibits ocular neovascularization","volume":"8","author":"Campochiaro","year":"2016","journal-title":"Sci Transl Med"},{"key":"R23-20261103","first-page":"683","article-title":"Gene therapy for retinal disease: Progress and prospects","volume":"30","author":"Rakoczy","year":"2019","journal-title":"Hum Gene Ther"},{"key":"R24-20261103","first-page":"981","article-title":"Suprachoroidal and subretinal AAV gene delivery for neovascular retinal disease","volume":"26","author":"Constable","year":"2020","journal-title":"Nat Med"},{"key":"R25-20261103","first-page":"73","article-title":"Nanocarriers for ocular drug delivery: Present status and future perspective","volume":"160","author":"Mishra","year":"2020","journal-title":"Adv Drug Deliv Rev"},{"key":"R26-20261103","first-page":"435","article-title":"Ocular pharmacokinetics and pharmacodynamics","volume":"7","author":"Schoenwald","year":"1990","journal-title":"Pharm Res"},{"key":"R27-20261103","first-page":"1123","article-title":"Dual functionalized liposomes for posterior segment ocular drug delivery","volume":"14","author":"Sun","year":"2024","journal-title":"Drug Deliv Transl Res"},{"key":"R28-20261103","first-page":"963","article-title":"Microneedle-assisted ocular drug delivery: Advances, challenges, and clinical potential","volume":"349","author":"Wu","year":"2022","journal-title":"J Control Release"},{"key":"R29-20261103","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1167\/iovs.14-14651","article-title":"Targeted drug delivery to the suprachoroidal space","volume":"55","author":"Kim","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R30-20261103","first-page":"36","article-title":"Suprachoroidal drug delivery using microneedles","volume":"5","author":"Patel","year":"2021","journal-title":"Ophthalmol Retina"},{"key":"R31-20261103","first-page":"43","article-title":"Suprachoroidal drug delivery for minimizing anterior segment exposure","volume":"182","author":"Chiang","year":"2017","journal-title":"Am J Ophthalmol"},{"key":"R32-20261103","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.ophtha.2020.01.006","article-title":"Suprachoroidal triamcinolone acetonide for uveitic macular edema","volume":"127","author":"Yeh","year":"2020","journal-title":"Ophthalmology"},{"key":"R33-20261103","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/IAE.0000000000000399","article-title":"Systemic pharmacokinetics of intravitreal anti-VEGF agents and implications for systemic exposure","volume":"34","author":"Avery","year":"2014","journal-title":"Retina"},{"key":"R34-20261103","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1586\/17512433.2014.884458","article-title":"Pharmacokinetics, pharmacodynamics and pre-clinical characteristics of ophthalmic drugs that bind VEGF","volume":"7","author":"Stewart","year":"2014","journal-title":"Expert Rev Clin Pharmacol"},{"key":"R35-20261103","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.preteyeres.2010.05.003","article-title":"Animal models of choroidal and retinal neovascularization","volume":"29","author":"Grossniklaus","year":"2010","journal-title":"Prog Retin Eye Res"},{"key":"R36-20261103","first-page":"698","article-title":"Drug eluting contact lenses for posterior segment drug delivery","volume":"6","author":"Maulvi","year":"2016","journal-title":"Drug Deliv Transl Res"}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_3226_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T19:00:37Z","timestamp":1793732437000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_3226_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/ijo.ijo_3226_25","relation":{},"ISSN":["0301-4738","1998-3689"],"issn-type":[{"value":"0301-4738","type":"print"},{"value":"1998-3689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,29]]},"assertion":[{"value":"2025-12-15","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-26","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}